CG
COGT icon

Cutler Group’s Cogent Biosciences COGT Stock Holding History

Cutler Group’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1K Buy
+3,500
New +$21.6K ﹤0.01% 1971
2022
Q3 		– Sell
-9,500
Closed -$4K – 4977
2022
Q2 		$4K Buy
+9,500
New +$64.8K ﹤0.01% 3829

Other funds holding COGT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Cutler Group's COGT Position: Q1 2024 in Review

Cutler Group reduced its Cogent Biosciences (COGT) stake by 45% in Q1 2024, selling an estimated $1.94K and leaving 386 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1813.

Cutler Group first reported a position in COGT in Q2 2022 and has held it in 6 quarters since. The position peaked at $67K in Q2 2022. 146 funds tracked by Wall St. Rank hold COGT as of Q1 2024.

  • Cutler Group held 386 shares of Cogent Biosciences worth $2K as of Q1 2024.
  • Cutler Group sold 314 Cogent Biosciences shares in Q1 2024, an estimated $1.94K.
  • Cogent Biosciences made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1813 holding.
  • Cutler Group first reported a position in Cogent Biosciences in Q2 2022 and has held it in 6 quarters since.
  • Cutler Group's Cogent Biosciences position peaked at $67K in Q2 2022.
  • 146 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.